Dr. Iskra Pusic, MD
Medical Oncology (Medical Oncology Physician)
4500 Forest Park Ave, Div Im Bone Marrow Transplant, 5th, 6th, 8th Fl
Saint Louis, MO 63108
- Medicare participating
At a glance
- Years since graduation
- 29
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 250
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MO license 2008009983
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Memorial Hospital Belleville, IL
Medical groups
- Washington University (3,029 clinicians)
- Washington University Physicians in Illinois Inc (175 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 250
- Services billed
- 22,933
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 12,240 | 15 |
| Injection, ferric carboxymaltose, 1 mg | 9,000 | 12 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 3,780 | 13 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 1,470 | 15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 722 | 39 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 476 | 85 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 408 | 25 |
| Injection, palonosetron hcl, 25 mcg | 240 | 16 |
| Injection, granisetron hydrochloride, 100 mcg | 220 | 17 |
| Established patient office or other outpatient visit, 30-39 minutes | 166 | 64 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Saint Louis, MO | 86 |
| Oxycodone Hcl Other prescribers in Saint Louis, MO | 75 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Saint Louis, MO | 44 |
| Fluconazole Other prescribers in Saint Louis, MO | 44 |
| Jakafi (ruxolitinib phosphate) | 43 |
| Ciprofloxacin Hcl Other prescribers in Saint Louis, MO | 41 |
| Venclexta (venetoclax) | 34 |
| Gabapentin Other prescribers in Saint Louis, MO | 30 |
| Rezurock (belumosudil mesylate) | 30 |
| Bosulif (bosutinib) | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 12 payments worth $12,319 in total to this clinician.
| Genzyme Corporation | $10,673 |
|---|---|
| National Marrow Donor Program | $1,525 |
| Jazz Pharmaceuticals Inc. | $121 |
| Consulting Fee | $10,451 |
|---|---|
| Travel and Lodging | $1,165 |
| Food and Beverage | $703 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Jun 14, 2025 | Consulting Fee | $9,251 |
| Genzyme Corporation Jun 7, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $771 |
| National Marrow Donor Program Jan 17, 2025 | Consulting Fee | $400 |
| National Marrow Donor Program Jun 20, 2025 | Consulting Fee | $400 |
| National Marrow Donor Program Oct 24, 2025 | Consulting Fee | $400 |
| Genzyme Corporation Jun 7, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $330 |
| Genzyme Corporation Jun 14, 2025 | Travel and Lodging travel to San Francisco, CA | $65.04 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $150,024 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Incyte Corporation - AGAVE-201, a phase 2, open-label, randomized, multicenter study to evaluate the efficacy, safety and tolerability of axatilimab at 3 different doses in patients with recurrent or refractory active chronic graft versus…
Syndax Pharmaceuticals, Inc. - A study to evaluate vimseltinib in adults with active chronic graft-versus-host disease (cgvhd)
Deciphera Pharmaceuticals Inc. - A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
National Marrow Donor Program - A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic…
National Marrow Donor Program - Facilitating Activation of Study Trials (FAST)
National Marrow Donor Program
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.